LivaNova PLC Q4 2025 Earnings Call Summary

Performance in 2025 was characterized by the third consecutive year of double-digit organic revenue growth, driven by the Essence heart-lung machine (HLM) rollout and market share gains in cardiopulmonary consumables. The cardiopulmonary segment's growth is being fueled by a global upgrade cycle, with Essence representing 55% of HLM units in 2025 and targeted to reach 80% of new placements by 2026. Management attributed epilepsy growth to strong commercial execution and the impact of the CORE VNS stud ...